Drugs / iode 131
iode 131
English name Iodine-131
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00435851 | Feb 2007 → ? | thyroid cancer | Gustave Roussy, Cancer Campus, Grand Paris | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-08-15 | Ipsen | Ipsen receives positive CHMP opinion for Cabometyx® in radioactive iodine-refractory differentiated thyroid cancer ipsen.com ↗ |
| 2022-05-03 | Ipsen | European Commission approves Cabometyx® as a second-line treatment for people living with radioactive iodine-refractory differentiated thyroid cancer ipsen.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iode 131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00435851 ↗ |
| Known as | (131)I | “we compared two thyrotropin-stimulation methods (thyroid hormone withdrawal and use of recombinant human thyrotropin) and two radioiodine ((131)I) doses (i.e., administered...” PMID 22551127 ↗ May 2012 |
| Known as | radioactive iodine | “In ESTIMABL1, a randomised phase 3 trial of radioactive iodine (131I) administration after complete surgical resection in patients with low-risk thyroid cancer” PMID 29807824 ↗ May 2018 |
| Known as | radioiodine | “we compared two thyrotropin-stimulation methods (thyroid hormone withdrawal and use of recombinant human thyrotropin) and two radioiodine ((131)I) doses (i.e., administered...” PMID 22551127 ↗ May 2012 |